A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III (Q5214489)
From MaRDI portal
!
This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use the normal view instead:
scientific article; zbMATH DE number 7165177
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III |
scientific article; zbMATH DE number 7165177 |
Statements
A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III (English)
0 references
7 February 2020
0 references
Bayesian design
0 references
clinical trial
0 references
dose finding
0 references
phase I-II clinical trial
0 references
phase III clinical trial
0 references
0.7785397171974182
0 references
0.7742869853973389
0 references
0.7611318826675415
0 references
0.7610808610916138
0 references
